MyrnaRitaNahasMD
Hematology • Boston, MAHematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Medical Director, Clinical Development
Dr. Nahas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
BIDMC
Boston, MA 02215
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2013 - 2016
UCLA David Geffen School of Medicine/UCLA Medical CenterChief Residency, Internal Medicine, 2012 - 2013- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2009 - 2012
The University of Texas Health Science Center at San AntonioClass of 2009
Certifications & Licensure
CA State Medical License 2011 - 2025
MA State Medical License 2014 - 2021- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Ruxolitinib + Allogeneic Stem Cell Transplantation in AML Start of enrollment: 2017 Nov 03
- Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma Start of enrollment: 2019 Feb 22
- Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts Start of enrollment: 2019 Aug 01
Publications & Presentations
PubMed
- 122 citationsMUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemiaAthalia Rachel Pyzer, Dina Stroopinsky, Hasan Rajabi, Abigail Washington, Ashujit Tagde
Blood. 2017-03-30 - 15 citationsLeukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia modelDina Stroopinsky, Jessica Liegel, Manoj Bhasin, Giulia Cheloni, Beena E Thomas
Haematologica. 2021-02-04 - 11 citationsMUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism.Dina Stroopinsky, Hasan Rajabi, Myrna Nahas, Jacalyn Rosenblatt, Maryam Rahimian
Journal of Cellular and Molecular Medicine. 2018-05-15
Abstracts/Posters
- T Cells Educated By DC/AML Fusions in the Context of 4-1BB Costimulation As a Potent Strategy for Adoptive Cellular TherapyMyrna Nahas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Development of Novel Second Generation DC/Tumor Fusion Vaccine in LymphomaMyrna Nahas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Na¥ve Patients with Relapsed or Refractory My...Myrna Nahas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Press Mentions
Ruxolitinib + Allogeneic Stem Cell Transplantation in AMLSeptember 18th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
